Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 3/20 | 0.44 |
| ▸ | CES1 | P23141 | 3/20 | 0.44 |
| ▸ | FABP4 | P15090 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5915249 | 0.89 | LMNA (0.52) | LMNAMAPK1POLBPKMPTPN1 | |
| SCHEMBL31107080 | 0.85 | LMNA (0.54) | LMNAMAPK1POLBPKMPTPN1 | |
| SCHEMBL11349953 | 0.85 | LMNA (0.54) | LMNAMAPK1POLBPKMPTPN1 | |
| SCHEMBL974064 | 0.85 | LMNA (0.54) | LMNAMAPK1POLBPKMPTPN1 | |
| SCHEMBL974062 | 0.85 | LMNA (0.54) | LMNAMAPK1POLBPKMPTPN1 | |
| SCHEMBL7522924 | 0.84 | LMNA (0.52) | LMNAMAPK1POLBPKMPTPN1 | |
| Ammonia Solution, Strong SCHEMBL7523599 | 0.84 | LMNA (0.52) | LMNAMAPK1POLBPKMPTPN1 | |
| SCHEMBL469655 | 0.84 | CES2 (0.63) | LMNAMAPK1POLBPKMPTPN1 | |
| SCHEMBL24732 | 0.84 | LMNA (0.52) | LMNAMAPK1KMT2ACYP2D6CES2 | |
| SCHEMBL24733 | 0.84 | LMNA (0.52) | LMNAMAPK1KMT2ACYP2D6CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220325035-A1 | POLYESTER, POLYESTERAMIDE, AND POLYAMIDE COMPOSITIONS | IYER ANANTH V (US) | 2022-10-13 | — | — | US | claimed |
| US-12623006-B2 | Medical instrument | TERUMO KABUSHIKI KAISHA (JP) | 2026-05-12 | — | — | US | disclosed |
| US-12554209-B2 | Toner particle with amorphous polyester resin | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12449742-B2 | Toner and method for manufacturing toner | CANON KABUSHIKI KAISHA (JP) | 2025-10-21 | — | — | US | disclosed |
| EP-3926408-B1 | IMAGE FORMING METHOD AND IMAGE FORMING SYSTEM | KONICA MINOLTA INC (JP) | 2025-09-24 | — | — | EP | disclosed |
| US-12405546-B2 | Toner | CANON KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| US-12372892-B2 | Toner particle with amorphous polyester resin | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2025-07-29 | — | — | US | disclosed |
| US-12282294-B2 | Toner particle with core particle and fine particles | HEWLETT-PACKARD DEVELOPMENT COMPANY, L.P. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20250021029-A1 | TONER, TONER CARTRIDGE, IMAGE FORMING APPARATUS, AND PRINTED ARTICLE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-01-16 | — | — | US | disclosed |
| US-12174584-B2 | Electrostatic charge image developing toner | Konica Minolta, Inc. (JP) | 2024-12-24 | — | — | US | disclosed |
| EP-1223951-A1 | METHOD OF PREVENTING ADHESIONS WITH ABSORBABLE POLYOXAESTERS | ETHICON, INC. (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6403655-B1 | Method of preventing adhesions with absorbable polyoxaesters | ETHICON, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20010012511-A1 | Method of preventing adhesions with absorbable polyoxaesters | BEZWADA RAO S (US) | 2001-08-09 | — | — | US | disclosed |
| US-6224894-B1 | MEDICAL EQUIPMENT | ETHICON, INC. | 2001-05-01 | — | — | US | disclosed |
| WO-2001012203-A1 | METHOD OF PREVENTING ADHESIONS WITH ABSORBABLE POLYOXAESTERS | ETHICON, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| US-6147168-A | Copolymers of absorbable polyoxaesters | ETHICON, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| US-6100346-A | Copolymers of polyoxaamides | ETHICON, INC. (US) | 2000-08-08 | — | — | US | disclosed |
| US-6074660-A | Absorbable polyoxaesters containing amines and/ or amido groups | ETHICON, INC. (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0804444-A1 | NOVEL MN(II) CARBOXYLATE COMPLEXES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS DISPROPORTIONATION CATALYSTS | Dublin Institute of Technology (IE) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996015136-A1 | NOVEL MN(II) CARBOXYLATE COMPLEXES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS DISPROPORTIONATION CATALYSTS | DUBLIN INSTITUTE OF TECHNOLOGY (IE) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012511-A1 | Method of preventing adhesions with absorbable polyoxaesters | EPCAM, CDH1, DSC1 | LMNA 2136/4885MAPK1 4424/4885POLB 3992/4885 |
| US-12623006-B2 | Medical instrument | MMAB, MIF, CD44 | LMNA 3546/4885MAPK1 4048/4885POLB 2052/4885 |
| US-12554209-B2 | Toner particle with amorphous polyester resin | MYD88, MSR1, CD14 | LMNA 2620/4885MAPK1 1575/4885POLB 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.